Telegraph Hill closes new health care investment fund
This article was originally published in Scrip
Telegraph Hill Partners (THP) backs life science, medical device and health care companies that support drug developers, researchers and physicians, and the San Francisco venture capital and growth equity firm will finance 10 to 15 private businesses with its new $310 million fund.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.